NCT02670330 - Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

June 9, 2015

Primary Completion Date

September 3, 2018

Study Completion Date

September 3, 2018

Conditions

Epidermolysis Bullosa

Interventions

DRUG

SD-101-6.0 cream

SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

Trial Locations (30)

2217

Kogarah

3052

Parkville

5020

Salzburg

11733

East Setauket

19104

Philadelphia

20016

Washington D.C.

27516

Chapel Hill

30173

Hanover

55455

Minneapolis

60611

Chicago

63110

St Louis

65212

Columbia

75015

Paris

78218

San Antonio

79104

Freiburg im Breisgau

80045

Aurora

85016

Phoenix

94063

Redwood City

98105

Seattle

45229-3039

Cincinnati

29425-5780

Charleston

1-06202

Nice

Unknown

Toulouse

Tel Aviv

Warsaw

Belgrade

Madrid

LT-50009

Kaunas

9713 GZ

Groningen

WC1N 3JH

London